PDCD1 and glioma: As gliomas have long been recognized as immunosuppressive neoplasms that are characterized by the activation of various immune escape mechanisms (reviewed by Razavi et al., 2016), our findings indicate that high levels of PD-1 promoter methylation might result in functional tumor-specific T cells effectively driving antitumor immune responses, therefore leading to a favorable course of disease.